Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145886 · ClinicalTrials.gov registry record · Phase 1
rhPTH Therapy for Low Turnover Bone Fragility
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00145886: Clinical Trial Phase 1 study, sponsored by University of Chicago.
NCT00145886 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00145886, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.
Primary Outcome
The effects on calcium balance will be examined at the beginning, after 3 months, and after 12 months of treatment with rhPTH. The rational for examining calcium balance at these three time points is that (at least in patients wit osteoporosis treated with PTH) the initial response is primarily an increase in bone formation; at 3 months there is also a proportionate increase in bone resorption; and at 12 months there is an established general increase in bone turnover.
Interventions
- DRUG rhPTH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2003-02 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Why NCT00145886 stopped before completion
NCT00145886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which rhPTH is the first listed.
NCT00145886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00145886 about?
NCT00145886 is a clinical study titled "rhPTH Therapy for Low Turnover Bone Fragility". The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.
What is the current status of trial NCT00145886?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2003-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00145886?
The interventions under investigation include: rhPTH (DRUG).
Who is sponsoring clinical trial NCT00145886?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00145886's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia